Arch Therapeutics, Inc.
ARTH · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -3% | -30.5% | 16.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 31.8% | 32.4% | 48.5% | 41.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -16,117.4% | -2,749.6% | -3,257.3% | -3,361.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -18,292.2% | -4,610.4% | -5,846.6% | -6,218.1% |
| EPS Diluted | -1.44 | -0.33 | -0.57 | -0.52 |
| % Growth | -336.4% | 42.1% | -9.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |